Stockscreener 앱 받기
16.76
2.51%
0.41
전일 마감가:
$16.35
열려 있는:
$16.39
하루 거래량:
1.45M
Relative Volume:
0.54
시가총액:
$1.19B
수익:
-
순이익/손실:
$-145.21M
주가수익비율:
-7.287
EPS:
-2.3
순현금흐름:
$-140.12M
1주 성능:
-9.36%
1개월 성능:
+9.26%
6개월 성능:
-68.09%
1년 성능:
-59.59%
1일 변동 폭
$16.18
$16.88
1주일 범위
$15.70
$18.80
52주 변동 폭
$5.95
$62.75
문레이크 이뮤노테라퓨틱스 Stock (MLTX) Company Profile
명칭
Moonlake Immunotherapeutics
전화
41 41 510 8022
주소
DORFSTRASSE 29, ZUG
MLTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
16.76 | 1.16B | 0 | -145.21M | -140.12M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
문레이크 이뮤노테라퓨틱스 Stock (MLTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-15 | 다운그레이드 | Goldman | Neutral → Sell |
| 2026-01-09 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2025-11-03 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-10-02 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-10-01 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-09-30 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-09-30 | 다운그레이드 | Wolfe Research | Outperform → Underperform |
| 2025-09-29 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2025-09-29 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-09-29 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-29 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-07-28 | 개시 | Rothschild & Co Redburn | Neutral |
| 2025-05-19 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-17 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-11-05 | 재개 | Wedbush | Outperform |
| 2024-08-26 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | 개시 | Oppenheimer | Outperform |
| 2024-04-02 | 개시 | Goldman | Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-08 | 개시 | Citigroup | Buy |
| 2023-11-02 | 개시 | Stifel | Buy |
| 2023-09-14 | 다운그레이드 | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | 개시 | Needham | Buy |
| 2023-06-15 | 개시 | Barclays | Equal Weight |
| 2023-05-01 | 개시 | Guggenheim | Buy |
| 2023-03-22 | 개시 | Wedbush | Outperform |
| 2023-03-09 | 개시 | BTIG Research | Buy |
| 2023-02-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-02 | 개시 | Bryan Garnier | Buy |
| 2022-11-11 | 개시 | Jefferies | Buy |
| 2022-08-25 | 개시 | SVB Leerink | Outperform |
| 2022-07-21 | 개시 | H.C. Wainwright | Buy |
| 2022-07-07 | 개시 | Cowen | Outperform |
모두보기
문레이크 이뮤노테라퓨틱스 주식(MLTX)의 최신 뉴스
MoonLake Immunotherapeutics (MLTX) Valuation After FDA BLA Green Light And Split Analyst Reactions - simplywall.st
Lost Money on MoonLake Immunotherapeutics (MLTX)? Contact Levi & Korsinsky Before December 15, 2025 to Join Class Action - TMX Newsfile
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap DownHere's Why - MarketBeat
Goldman Sachs downgrades Moonlake Immunotherapeutics stock to Sell on HS approval concerns By Investing.com - Investing.com South Africa
MoonLake downgraded to Sell at Goldman Sachs (MLTX:NASDAQ) - Seeking Alpha
Goldman Sachs Downgrades MLTX, Raises Price Target to $10.00 | M - GuruFocus
Goldman Sachs downgrades Moonlake Immunotherapeutics stock to Sell on HS approval concerns - Investing.com Canada
MoonLake Immunotherapeutics downgraded to Sell from Neutral at Goldman Sachs - TipRanks
MACD Signal: Is MoonLake Immunotherapeutics stock suitable for long term investingTrade Risk Summary & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Stop Loss: Is IGMS benefiting from interest rate changes2025 Big Picture & Detailed Earnings Play Strategies - baoquankhu1.vn
Exit Recap: Will MoonLake Immunotherapeutics stock continue upward momentumOil Prices & Safe Capital Growth Stock Tips - moha.gov.vn
Death Cross: How is MoonLake Immunotherapeutics managing supply chain issues2025 Bull vs Bear & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Buyback Watch: What is the Moat Score of MoonLake ImmunotherapeuticsMarket Sentiment Summary & Risk Controlled Stock Alerts - baoquankhu1.vn
Guidance Update: Why MoonLake Immunotherapeutics stock could rally in 2025Take Profit & AI Powered Market Trend Analysis - Bộ Nội Vụ
MLTX Stock Erases Most Of 2025 Loses As Wall Street, Retail Bets On FDA Feedback For Sonelokimab - Stocktwits
Published on: 2026-01-13 06:01:31 - Улправда
(MLTX) Risk Channels and Responsive Allocation - Stock Traders Daily
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 7.3%Time to Sell? - MarketBeat
MLTX Stock Extends Rally As FDA Feedback Spurs Bullish Brokerage Action – Retail Speculates On Potential M&A Conversations - Stocktwits
MLTX stock extends rally as FDA feedback spurs bullish brokerage action – retail speculates on potential M&A conversations - MSN
Why MoonLake Immunotherapeutics (MLTX) Is Up 54.7% After FDA Opens Path to HS BLA Filing - simplywall.st
H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Raises Target Price to $32 - 富途牛牛
BTIG Upgrades MoonLake Immunotherapeutics(MLTX.US) to Buy Rating, Announces Target Price $24 - 富途牛牛
MoonLake Immunotherapeutics (MLTX) Valuation After FDA Clears Existing Data For Sonelokimab BLA In Hidradenitis Suppurativa - simplywall.st
A Quick Look at Today's Ratings for MoonLake Immunotherapeutics(MLTX.US), With a Forecast Between $20 to $45 - 富途牛牛
MoonLake Options Trading: A Deep Dive into Market Sentiment - Benzinga
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Up 9.6%Time to Buy? - MarketBeat
Insmed’s ‘ginormous’ lung drug sales; J&J’s US pricing deal - BioPharma Dive
MoonLake Immunotherapeutics Surges as FDA "De-Risks" Sonelokimab, Reigniting Multi-Billion Dollar Takeover Speculation - FinancialContent
Tranquility Restored For MoonLake With Positive FDA Feedback On HS Drug - Citeline News & Insights
MoonLake Immunotherapeutics upgraded to Buy from Neutral at BTIG - TipRanks
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Buy Rating at HC Wainwright - MarketBeat
MoonLake: Positive FDA Meeting Spurs Momentum Ahead Of BLA Submission (NASDAQ:MLTX) - Seeking Alpha
MLTX Analyst Rating: HC Wainwright & Co. Raises Price Target to $32.00 | MLTX Stock News - GuruFocus
BTIG Upgrades MoonLake Immunotherapeutics (MLTX) - Nasdaq
Moonlake Immunotherapeutics stock upgraded to Buy at BTIG on FDA feedback - Investing.com Nigeria
Will MoonLake's Clinical Milestones Send Investors Over The Moon? - RTTNews
Will MoonLake Immunotherapeutics stock benefit from AI adoptionJuly 2025 Update & High Conviction Trade Alerts - ulpravda.ru
MoonLake Immunotherapeutics stock price target raised to $45 by Clear Street By Investing.com - Investing.com South Africa
MoonLake Immunotherapeutics (MLTX) Is Up 20.0% After FDA Clears Existing SLK Data For HS BLA Path - Yahoo Finance
What margin trends mean for MoonLake Immunotherapeutics stockQuarterly Trade Review & High Conviction Investment Ideas - ulpravda.ru
Will MoonLake Immunotherapeutics stock reach all time highs in 2025CEO Change & Growth Focused Entry Reports - ulpravda.ru
Will MoonLake Immunotherapeutics stock benefit from sector rotationWeekly Gains Summary & Low Drawdown Momentum Trade Ideas - ulpravda.ru
MoonLake Immunotherapeutics Stock Collapses. Why It’s Down 88%. - MSN
Biopharma bites: A flurry of financings headlined by Diagonal, plus updates from Servier, MoonLake - FirstWord
MoonLake stock jumps after FDA feedback clears path for sonelokimab filing without new HS trials - TechStock²
Will MoonLake Immunotherapeutics stock rally after Fed decisionsMarket Sentiment Report & Consistent Profit Trading Strategies - ulpravda.ru
Why MoonLake Immunotherapeutics stock could rally in 20252025 Top Gainers & Safe Investment Capital Preservation Plans - ulpravda.ru
MoonLake Immunotherapeutics: HS Regulatory De-Risking and 2026 Inflammatory Disease Catalysts Support Buy Rating - TipRanks
MoonLake Catapults On FDA Deal For Its Down-And-Out Skin Disease Drug - Investor's Business Daily
MoonLake soars 45% after FDA clears path for key skin drug | Tap to know more | Inshorts - Inshorts
문레이크 이뮤노테라퓨틱스 (MLTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
문레이크 이뮤노테라퓨틱스 주식 (MLTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Santos da Silva Jorge | Chief Executive Officer |
Dec 09 '25 |
Sale |
14.49 |
70,000 |
1,014,300 |
2,878,577 |
| Reich Kristian | Chief Scientific Officer |
Dec 08 '25 |
Sale |
15.08 |
130,000 |
1,960,400 |
72,908 |
| Reich Kristian | Chief Scientific Officer |
Dec 09 '25 |
Sale |
14.43 |
72,908 |
1,052,062 |
0 |
4.73%
0.92%
자본화:
|
볼륨(24시간):